In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
about
Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitroTelomere disruption results in non-random formation of de novo dicentric chromosomes involving acrocentric human chromosomes.Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.Nucleolar organization, ribosomal DNA array stability, and acrocentric chromosome integrity are linked to telomere function.DNA topoisomerases participate in fragility of the oncogene RET.The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant.P19ARF and RasV¹² offer opposing regulation of DHX33 translation to dictate tumor cell fateAn ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.Mitochondrial topoisomerase I sites in the regulatory D-loop region of mitochondrial DNA.The cell's nucleolus: an emerging target for chemotherapeutic intervention.Distinct effects of topoisomerase I and RNA polymerase I inhibitors suggest a dual mechanism of nucleolar/nucleoplasmic partitioning of topoisomerase I.The Nse5-Nse6 dimer mediates DNA repair roles of the Smc5-Smc6 complexDNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin.Nucleolar disruption leads to the spatial separation of key 18S rRNA processing factors.
P2860
Q28910347-73D433AC-243C-4151-8F40-1E6DCD9CEA5DQ33658678-FA070C29-BDFE-4CA4-9C81-63BFEF69C9DAQ33963811-2E116113-DBAB-4AFC-BF60-1CE419BB227DQ34411779-801BA121-4F07-4AAD-B7EE-9A1AA9A9B48FQ34990644-73E3FF0E-A084-4A31-B40B-B4955EE456E9Q35130480-9D4203C7-0ED9-4AFD-8FFC-B1968243493EQ36759830-154FFF7A-4C5C-4E20-B353-4ED5E4E42D15Q36853869-F39B2AC8-75C5-44CA-8EEB-61664F03E7A0Q37001842-A4A6DE12-B9FB-4A60-A0C6-4E1DF4469E98Q37484539-28AC6582-4E9F-41A8-8DF8-EFF0FFE4A788Q40579913-50543747-F5D8-486C-90D2-CABF3206AD68Q41971877-CD619159-CB45-457F-825B-1FEF19F073D6Q42623345-8D262F5A-BCF1-41F5-9720-F586414C8AF2Q45716745-746625DF-7F1E-4C65-828F-7E294C7A2832
P2860
In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@ast
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@en
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@nl
type
label
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@ast
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@en
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@nl
prefLabel
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@ast
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@en
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@nl
P2093
P2860
P356
P1476
In vivo sequencing of camptoth ...... n human colon carcinoma cells.
@en
P2093
Fujimori A
Pondarré C
Strumberg D
Torres-León R
P2860
P304
P356
10.1093/NAR/25.20.4111
P407
P577
1997-10-01T00:00:00Z